DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

Not Applicable

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Interventions: Drug: Yishen Qutong Granules
Drug: Yishen Qutong Simulant Granules

First Posted Date: 2025-03-07

Last Posted Date: 2025-03-07

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 536

Registration Number: NCT06863831

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, Chaoyang, China

Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Treatment group
Drug: Standard-of-care control group

First Posted Date: 2025-03-05

Last Posted Date: 2025-03-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 130

Registration Number: NCT06858969

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

Not yet recruiting

Conditions: Colorectal Cancer

First Posted Date: 2025-03-05

Last Posted Date: 2025-03-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 200

Registration Number: NCT06858956

Ivonescimab Plus Chemotherapy in Patients with Initially Unresectable Colorectal Cancer Liver Metastases

Phase 2

Recruiting

Conditions: Colorectal Liver Metastases

Interventions: Drug: Ivonescimab plus chemotherapy

First Posted Date: 2025-02-27

Last Posted Date: 2025-02-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT06848842

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Ursodeoxycholic Acid (URSO)
Radiation: Radiotherapy
Drug: Adebrelimab (PD-L1 inhibitor)

First Posted Date: 2025-02-24

Last Posted Date: 2025-02-24

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 70

Registration Number: NCT06842472

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis

Phase 2

Not yet recruiting

Conditions: Brain Metastasis from Advanced HER2-negative Breast Cancer

Interventions: Drug: Adelumab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy
Drug: Adelumab+VEX Metronomic Chemotherapy+Delayed Radiotherapy

First Posted Date: 2025-02-21

Last Posted Date: 2025-02-21

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT06839560

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing 100021, Beijing, Beijing, China

A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.

Not yet recruiting

Conditions: Advanced Breast Cancer Brain Metastasis

First Posted Date: 2025-02-21

Last Posted Date: 2025-02-21

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT06839547

Jianzhong Qushi in Chronic RRI

Phase 3

Not yet recruiting

Conditions: Chronic Radiation Proctitis

Interventions: Drug: Jianzhong Qushi Formula
Drug: Placebo

First Posted Date: 2025-02-20

Last Posted Date: 2025-02-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 168

Registration Number: NCT06837597

Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002

Not Applicable

Not yet recruiting

Conditions: NF2 Deficiency

First Posted Date: 2025-02-19

Last Posted Date: 2025-02-19

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 9

Registration Number: NCT06834438

Locations: 🇨🇳
Shuhang Wang, Beijing, Beijing, China

Familial Breast Cancer in China

Not yet recruiting

Conditions: Breast Carcinoma
Genetic Variation

First Posted Date: 2025-02-18

Last Posted Date: 2025-02-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT06833216

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy